Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Episciences Inc
WARNING LETTER
•Episciences Inc•March 11, 2022

Episciences Inc – FDA Warning Letter, Mar 11, 2022

Record Details

The FDA inspected Episciences Inc. in Boise, ID, from March 7-11, 2022, identifying significant Current Good Manufacturing Practice (CGMP) violations for finished pharmaceuticals, rendering their drug products adulterated under 21 U.S.C. 351(a)(2)(B). The firm's response to the FDA 483 was deemed inadequate. Key violations include the failure to thoroughly investigate out-of-specification (OOS) laboratory results with scientifically supported conclusions and corrective actions (21 CFR 211.192). The firm also failed to establish and follow adequate written procedures for production and process control, specifically lacking proper validation for OTC drug manufacturing processes (21 CFR 211.100(a) & 211.100(b)). Furthermore, Episciences did not perform appropriate laboratory determination of satisfactory conformance to final specifications, including identity, strength, and microbiological testing, for each drug product batch prior to release (21 CFR 211.165(a) & 211.165(b)), a repeat observation. Lastly, the firm failed to conduct identity testing for each component lot and adequately establish supplier reliability (21 CFR 211.84(d)(1) & 211.84(d)(2)). The FDA strongly recommended engaging a CGMP consultant. The firm must respond within 15 working days with a detailed plan for corrective actions and recurrence prevention, or face potential regulatory actions like seizure, injunction, and withholding of export certificates or new application approvals.

Company
Episciences Inc
Inspection date
March 11, 2022
Product type
Drugs
Office
Division of Pharmaceutical Quality Operations IV
Person
  • Steven E. Porter (Program Division Director)
View Company Profile

ID · 124a1c66-a49e-4963-a85a-e9fa50544eac

Violation Codes10
21 CFR 21021 CFR 21121 CFR 211.19221 CFR 211.100(a)21 CFR 211.100(b)21 CFR 211.165(a)21 CFR 211.165(b)21 CFR 211.84(d)(1)21 CFR 211.84(d)(2)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Episciences Inc
  • 483 - 2024-01-29January 29, 2024
  • 483 - 2022-03-11March 11, 2022
  • WARNING_LETTER - 2015-12-31December 31, 2015

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Episciences Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.